Emmanuel B Walter1, Christoph P Hornik2, Lisa Grohskopf3, Charles E McGee4, Christopher A Todd4, Oidda I Museru5, Lynn Harrington4, Karen R Broder5. 1. Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA; Duke Clinical Research Institute, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA. Electronic address: walte002@mc.duke.edu. 2. Duke Clinical Research Institute, Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA. 3. Epidemiology and Prevention Branch, Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA. 4. Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA. 5. Immunization Safety Office, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.
Abstract
BACKGROUND:Antipyretics reduce fever following childhood vaccinations; after inactivated influenza vaccine (IIV) they might ameliorate fever and thereby decrease febrile seizure risk, but also possibly blunt the immune response. We assessed the effect of antipyretics on immune responses and fever following IIV in children ages 6 through 47 months. METHODS: Over the course of three seasons, one hundred forty-two children, receiving either a single or the first of 2 recommended doses of IIV, were randomized to receive either oral acetaminophen suspension (n = 59) or placebo (n = 59) (double-blinded) or ibuprofen (n = 24) (open-label) immediately following IIV and every 4-8 h thereafter for 24 h. Blood samples were obtained at enrollment and 4 weeks following the last recommended IIV dose. Responses to IIV were assessed by hemagglutination inhibition assay (HAI). Seroprotection was defined as an HAI titer ≥1:40 and seroconversion as a titer ≥1:40 if baseline titer <1:10 or four-fold rise if baseline titer ≥1:10. Participants were monitored for fever and other solicited symptoms on the day of and day following IIV. RESULTS: Significant differences in seroconversion and post-vaccination seroprotection were not observed between children included in the different antipyretic groups and the placebo group for the vaccine antigens included in IIV over the course of the studies. Frequencies of solicited symptoms, including fever, were similar between treatment groups and the placebo group. CONCLUSIONS: Significant blunting of the immune response was not observed when antipyretics were administered to young children receiving IIV. Studies with larger sample sizes are needed to definitively establish the effect of antipyretics on IIV immunogenicity.
RCT Entities:
BACKGROUND: Antipyretics reduce fever following childhood vaccinations; after inactivated influenza vaccine (IIV) they might ameliorate fever and thereby decrease febrile seizure risk, but also possibly blunt the immune response. We assessed the effect of antipyretics on immune responses and fever following IIV in children ages 6 through 47 months. METHODS: Over the course of three seasons, one hundred forty-two children, receiving either a single or the first of 2 recommended doses of IIV, were randomized to receive either oral acetaminophen suspension (n = 59) or placebo (n = 59) (double-blinded) or ibuprofen (n = 24) (open-label) immediately following IIV and every 4-8 h thereafter for 24 h. Blood samples were obtained at enrollment and 4 weeks following the last recommended IIV dose. Responses to IIV were assessed by hemagglutination inhibition assay (HAI). Seroprotection was defined as an HAI titer ≥1:40 and seroconversion as a titer ≥1:40 if baseline titer <1:10 or four-fold rise if baseline titer ≥1:10. Participants were monitored for fever and other solicited symptoms on the day of and day following IIV. RESULTS: Significant differences in seroconversion and post-vaccination seroprotection were not observed between children included in the different antipyretic groups and the placebo group for the vaccine antigens included in IIV over the course of the studies. Frequencies of solicited symptoms, including fever, were similar between treatment groups and the placebo group. CONCLUSIONS: Significant blunting of the immune response was not observed when antipyretics were administered to young children receiving IIV. Studies with larger sample sizes are needed to definitively establish the effect of antipyretics on IIV immunogenicity.
Authors: Kathleen M Neuzil; Lisa A Jackson; Jennifer Nelson; Alexander Klimov; Nancy Cox; Carolyn B Bridges; John Dunn; Frank DeStefano; David Shay Journal: J Infect Dis Date: 2006-09-11 Impact factor: 5.226
Authors: Nick J Andrews; Woolf T Walker; Adam Finn; Paul T Heath; Andrew C Collinson; Andrew J Pollard; Matthew D Snape; Saul N Faust; Pauline A Waight; Katja Hoschler; Liz Sheasby; Claire Waddington; Simon Kerridge; Jeremy Chalk; Amanda Reiner; Tessa John; Margaret Fletcher; Ruth Allen; Natalie Fineman; Su Wilkins; Michelle Casey; Louise Michaelis; Clarissa Oeser; Ifeanyichukwu Okike; Shamez Ladhani; Elizabeth Miller Journal: Vaccine Date: 2011-08-27 Impact factor: 3.641
Authors: Nicola P Klein; Bruce Fireman; W Katherine Yih; Edwin Lewis; Martin Kulldorff; Paula Ray; Roger Baxter; Simon Hambidge; James Nordin; Allison Naleway; Edward A Belongia; Tracy Lieu; James Baggs; Eric Weintraub Journal: Pediatrics Date: 2010-06-29 Impact factor: 7.124
Authors: Margaret A Maglione; Lopamudra Das; Laura Raaen; Alexandria Smith; Ramya Chari; Sydne Newberry; Roberta Shanman; Tanja Perry; Matthew Bidwell Goetz; Courtney Gidengil Journal: Pediatrics Date: 2014-07-01 Impact factor: 7.124
Authors: Lisa A Jackson; Do Peterson; John Dunn; Simon J Hambidge; Maya Dunstan; Patty Starkovich; Onchee Yu; Joyce Benoit; Clara P Dominguez-Islas; Barbara Carste; Patti Benson; Jennifer C Nelson Journal: PLoS One Date: 2011-06-17 Impact factor: 3.240
Authors: Lisa A Grohskopf; Leslie Z Sokolow; Sonja J Olsen; Joseph S Bresee; Karen R Broder; Ruth A Karron Journal: MMWR Morb Mortal Wkly Rep Date: 2015-08-07 Impact factor: 17.586
Authors: Victoria C Ziesenitz; Tatjana Welzel; Madelé van Dyk; Patrick Saur; Matthias Gorenflo; Johannes N van den Anker Journal: Paediatr Drugs Date: 2022-09-02 Impact factor: 3.930
Authors: Eng Eong Ooi; Arti Dhar; Richard Petruschke; Camille Locht; Philippe Buchy; Jenny Guek Hong Low Journal: NPJ Vaccines Date: 2022-03-02 Impact factor: 9.399